Further preclinical studies are needed to determine the clinical applicability of HMGCLL1 or CDK4/6 inhibition in CML to improve DMR rates and enhance LSCs eradication. This evidence concerns the gene CDK4 and chronic myelogenous leukemia, BCR-ABL1 positive.